A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates

Author:

Landry Marie L.1,Stanat Sylvia2,Biron Karen2,Brambilla Donald3,Britt William4,Jokela Janet5,Chou Sunwen6,Drew W. Lawrence7,Erice Alejo8,Gilliam Bruce9,Lurain Nell10,Manischewitz Jody11,Miner Richard7,Nokta Mostafa12,Reichelderfer Patricia13,Spector Stephen14,Weinberg Adriana15,Yen-Lieberman Belinda16,Crumpacker Clyde5,

Affiliation:

1. Yale University, New Haven, Connecticut1;

2. Glaxo Wellcome, Research Triangle Park, North Carolina2;

3. New England Research Institute, Watertown, Massachusetts3;

4. University of Alabama, Birmingham, Alabama4;

5. Harvard University, Boston, Massachusetts5

6. University of Oregon, Portland, Oregon6;

7. University of California, San Francisco, California7;

8. University of Minnesota, Minneapolis, Minnesota8;

9. University of North Carolina, Chapel Hill, North Carolina9;

10. Rush Medical College, Chicago, Illinois10;

11. National Institutes of Health and Food and Drug Administration,11and

12. University of Texas, Galveston, Texas12;

13. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health,13 Bethesda, Maryland;

14. University of California, San Diego, California14;

15. University of Colorado, Denver, Colorado15;

16. Cleveland Clinic Foundation, Cleveland, Ohio16; and

Abstract

ABSTRACT Twelve laboratories collaborated in formulating and testing a standardized plaque reduction assay for cytomegalovirus (CMV) cell-associated clinical isolates. Four characterized and plaque-purified CMV strains, as well as six coded clinical isolates obtained after antiviral therapy, were distributed and tested. Good agreement was obtained for four of the clinical isolates, but a broad distribution of results was obtained for two isolates. Analysis of these results indicates the problems associated with clinical isolates, including the large genetic variability and the highly cell-associated phenotype. This collaborative effort, by addressing these problems, represents a significant step toward the development of a standardized assay.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference13 articles.

1. Analysis of the UL97 phosphotransferase coding sequence in clinical cytomegalovirus isolates and identification of mutations conferring ganciclovir resistance.;Chou S.;J. Infect. Dis.,1995

2. Chou T. C. The median-effect principle and the combination index for quantitation of synergism and antagonism Synergism and antagonism in chemotherapy. Rideout D. C. Chou T. C. 1991 61 102 Academic Press San Diego Calif

3. Prevalence of resistance in patients receiving ganciclovir for serious cytomegalovirus infection.;Drew W. L.;J. Infect. Dis.,1991

4. Progressive disease due to ganciclovir resistant cytomegalovirus in immunocompromised patients.;Erice A.;N. Engl. J. Med.,1989

5. Antiviral susceptibilities and analysis of UL97 and DNA polymerase sequences of clinical cytomegalovirus isolates from immunocompromised patients.;Erice A.;J. Infect. Dis.,1997

Cited by 121 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3